BioSmart
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
BioSmart makes smart cards, the chip-embedded plastic cards used for credit and payment transactions, and operates several other distinct businesses including pharmaceuticals, alcohol-payment systems, book publishing, diagnostic kits, and heavy-electrical-equipment manufacturing and repair.
Its products and services reach consumers and businesses across these varied industries. Listed on KOSDAQ, Korea's tech and small-cap exchange, the company deliberately spans unrelated sectors as a strategy to manage the risks that come with operating in a mature, slow-growth core market.
Summary is AI-generated and may contain errors · figures from DART filings
BioSmart in five facts
What does BioSmart do?
BioSmart makes smart cards, the chip-embedded plastic cards used for credit and payment transactions, and operates several other distinct businesses including pharmaceuticals, alcohol-payment systems, book publishing, diagnostic kits, and heavy-electrical-equipment manufacturing and repair.
Where is BioSmart listed and in which sector?
BioSmart (Korean name: 바이오스마트) trades under KRX code 038460 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Information Technology sector, Components.
How large is BioSmart?
Its market capitalisation was US$50.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were BioSmart's latest annual revenue and operating profit?
For fiscal year 2025, BioSmart reported revenue of US$364.4M, operating profit of US$17M and net income of US$6.8M, per its annual report on DART (data retrieved from DART on 2026-06-04). Revenue was down 0.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-04
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersSep 9
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
BioSmart reported consolidated results for FY2025: revenue of US$327M (−0.3% year on year), operating profit of US$15.3M (+11.5% year on year) and net income of US$6.09M (+751.5% year on year).
Earnings · Mar 12